Coeptis Therapeutics, Inc.
COEP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -17,086.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -17,932.4% |
| EPS Diluted | -5.65 | -0.83 | -2.87 | -13.16 |
| % Growth | -580.7% | 71.1% | 78.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |